A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

International Journal of Infectious Diseases

Ahmedul Kabir¹  Jyoti Somani²  Allen G. Ross³  Sabeena Ahmed³  Mohammad Mahbubul Karim³  Mariya Kibtiya Sumiya³  Mohammad Sharif Hossain³  Mustafizur Rahman³  Wasif Ali Khan³  John D. Clemens³  Ching Swe Phru³  Asma Binte Aziz³  Khalequ Zaman³  Mohammad Abul Hasnat⁴  Rubina Yasmin⁵ 

[1] Dhaka Medical College and Hospital, Dhaka, Bangladesh;Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore;International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh;Kurmitola General Hospital, Dhaka, Bangladesh;Mugda Medical College and Hospital, Dhaka, Bangladesh;

关键词: Ivermectin;    Doxycycline;    COVID-19;    SARS-CoV-2;    Bangladesh;   

DOI  :  

来源: DOAJ

【 摘 要 】

Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.

【 授权许可】

Unknown